Prognostic variables in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy

Medical and Pediatric Oncology

Volumn 26, Issue 5, 1996, Pages 305-317

  Fountzilas, George ^a,d   Gossios, Konstantinos ^c   Zisiadis, Alkis ^a   Svarna, Eugenia ^c   Skarlos, Dimosthenis ^b   Pavlidis, Nicholas ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

chemotherapy; colorectal cancer; prognostic factors

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA2B INTERFERON; CARCINOEMBRYONIC ANTIGEN; DIPYRIDAMOLE; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; AGED; ANALYSIS OF VARIANCE; COLORECTAL TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029665155     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199605)26:5<305::AID-MPO2>3.0.CO;2-M     Document Type: Article

References (45)

1. Petrelli N, Herrera L, Rustum Y, Burna P, Creaven P, Stulc J, Emrich LJ, Mittelman A: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987.
2. Gastrointestinal Tumor Study Group: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7:119-126, 1989.
3. Erlichman C, Fine S, Wong A, Elhakim T: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988.
4. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1417, 1989.
5. Valone FH, Friedman MA, Wittlinger PS, Drakes T, Eisenberg PD, Malec M, Hannigan JF, Brown BW Jr: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil and leucovorin: A randomized trial of the Northem California Oncology Group. J Clin Oncol 7:1427-1436, 1989.
6. Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D, Odujmrin O, DeLap R, Shuster J, Newman E. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990.
7. Labianca R, Pancera G, Aitini E, Barni S, Beretta A, Beretta GD, Cesana B, Cornella G, Cozzaglio L, Cristoni M, Spagnolli P, Frontini L, Gottardi O, Martignoni G, Scapaticci R, Smerieri F, Vinci M, Zadro A, Zaniboni A, Luporini G: Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of "GISCAD" (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 2:673-679, 1991.
8. Di Constanzo F, Bartolucci R, Calabresi F, Sofra M, Marzola M, Belsanti V, Boni C, Bacchi M: Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 3:371-376, 1992.
9. Loffler TM, Korsten FW, Planker M, Reis HE, Burghard F, Albert E, Lindeman W, Schroder M, Hausamen TU, Strohmey G: Fluorouracil as monotherapy or combined with folic acid in metastatic colorectal carcinoma. Deutsch Med Wochenschr 117:1007-1013, 1992.
10. Nobile MT, Risso R, Sertoli MR, Bubagott A, Vidili MG, Guglielm A, Venturin M, Canobbio L, Fassio T, Gallo L: Randomized comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 11:1823-1827, 1992.
11. Fountzilas G, Zisiadis A, Kosmidis P, Basdanis G, Makrantonakis P, Paspatis A, Tsavdaridis D, Tsavaris N, Aletras O, Tourkantonis A: High-dose leucovorin, fluorouracil and oral dipyridamole in the treatment of advanced colorectal cancer. Anticancer Res 11:865-868, 1991.
12. Komidis P, Tsavaris N, Skarlos D, Pavlidis N, Beer M, Theocharis D, Samanta D, Briasoulis E, Fountzilas G: Fluorouracil and follinic acid with or without a2b-interferon in advanced colorectal cancer. A prospective randomized trial (abstr). Proc Am Soc Clin Oncol 12:211, 1993.
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
14. Mantel M: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
15. Cox DR: Regression models and life tables. J R Statist Soc 34 (Series B): 187-220, 1972.
16. Andersen PK: Testing goodness of fit of Cox's regression and life model. Biometrics 38:67-77, 1982.
17. Chatterjee S, Price B (eds): "Regression Analysis by Example." New York: John Wiley, 1977, pp. 157-163.
18. Hosmer DW, Lemeshow S (eds): "Applied Logistic Regression." New York: John Wiley, 1989.
19. Dixon WJ, Brown MB, Engleman L (eds): "BMDP Statistical Software Manual." Los Angeles: University of California Press, 1990.
20. Machin D, Campbel MJ (eds): "Statistical Tables for the Design of Clinical Trials." Oxford: Blackwell Scientific, 1987, pp. 10-34 and 94-130.
21. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991.
22. De Leon MP, Sant M, Micheli A, Sacchetti C, Di Gregorio C, Fante R, Zanghieri G, Melotti G, Gatta G: Clinical and pathological prognostic indicators in colorectal cancer. A population-based study. Cancer 69:626-635, 1992.
23. Lavin P, Mittleman A, Douglas H, Engstrom P, Klaassen D: Survival and response to chemotherapy for advanced colorectal adenocarcinoma. Cancer 46:1536-1543, 1980.
24. Kemeny N, Braum DW Jr: Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood count. Am J Med 74:786-794, 1983.
25. Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson RW, Valone F, Labianca R, Doroshow JH, Petrelli N: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992.
26. Piedbois P, Buyse M: What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Ann Oncol 4 (Suppl 2):S15-S19, 1993.
27. Erlichman C, Fine S, Kerr I, Hoffman W, Gorg C: A phase II trial of 5-fluorouracil and I-leucovorin. A multicentre experience. In Rustum YM, Moran R (eds): "Novel Approaches to Selective Treatment of Human Solid Tumors: Laboratory and Clinical Correlation." Proceedings of an International Symposium. Buffalo, NY: Roswell Park Cancer Institute Press, 1992, pp. 30-32.
28. Rosso R, Mazzei T, Sobrero A, Mini E, Cartei G, Conte P, Labianca R, Cartei F, Falcone A, Pancera G, Barsanti G, Di Constanze F, Gugliemi A, Bolli E, Tixi L, Aschele C, Ribecco A, Periti P: Phase II trial of 5-fluorouracil and the natural I isomer of folinic acid in the treatment of advanced colorectal carcinoma. Eur J Cancer 30A:338-343, 1994.
29. Kohne C-H, Hiddemann W, Schuller J, Weiss J, Lohrmann H-P, Schmitz-Hubner U, Bodenstein H, Schober C, Wilke H, Grem J, Schmoll H-J: Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: A prospective randomized study. J Clin Oncol 13:1201-1208, 1995.
30. Buroker TR, O'Connell MJ, Wieand S, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994.
31. Steinberg J, Erlichman C, Gadalla T, Fine S, Wong A: Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 28A:1817-1820, 1992.
32. Fortner JG, Silva JS, Cox EB, Goldbey RB, Gallowitz H, Maclean BJ: Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. III Treatment by intrahepatic chemotherapy. Ann Surg 199:317-324, 1984.
33. Ekberg H, Tranberg KG, Lundstedt C, Hanff G, Ranstam J, Jeppsson B, Bengmark S: Determinants of survival after intraarterial infusion of 5-fluorouracil for liver metastases from colorectal cancer: A multivariate analysis. J Surg Oncol 31:246-254, 1986.
34. Chang AE, Steinberg SM, Culnane M, White DE: Determinants of survival in patients with unresectable colorectal liver metastases. J Surg Oncol 40:245-251, 1989.
35. Wood CB, Gillis CR, Blumgart LH: A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2:285-288, 1976.
36. Bengtsson G, Carlsson G, Goran B, Hatstrom L, Johnson P-E: Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 141:586-589, 1981.
37. Boey J, Choi TK, Wang J, Ong GB: Carcinoma of the colon and rectum with liver involvement. Surg Gynecol Obstet 153:864-868, 1981.
38. Goslin R, Steele G, Zamcheck N, Mayer R, Macintyre J: Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 25:749-754, 1982.
39. Lahr CI, Soong SJ, Cloud GC, Smith JW, Urist MM, Balch CM: A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol 1:720-726, 1983.
40. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM: The natural history of hepatic metastases from colorectal cancer. Ann Surg 199:502-508, 1984.
41. Arnaud JP, Dumont P, Adloff M, Leguillou A, Py JM: Natural history of colorectal carcinoma with untreated liver metastases. Surg Gastroenterol 3:37-42, 1984.
42. Finan PJ, Marshall RJ, Cooper EH, Giles GR: Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: A clinical and computer analysis. Br J Surg 72:373-377, 1985.
43. Kemeny N, Niedzwiecki D, Shurgot B, Oderman P: Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. Cancer 63:742-747, 1989.
44. Tartter PI: Pretreatment prognostic factors in colorectal cancer patients with liver metastases. Eur J Surg Oncol 13:485-491, 1987.
45. De Braun LM, Van de Velde CJH, Bouwhuis-Hoogerwere ML, Zwaveling A: Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol 34:81-86, 1987.